Aardvark Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4370 La Jolla Village Dr Ste 1050, San D...Phone Number
(858) 225-7696Website
www.aardvarktherapeutics.comRevenue
$7 MillionStock Symbol
AARDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Aardvark Therapeutics
Founded in 2017, Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications. The company is headquartered in San Diego, California.Explore more
Aardvark Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aardvark Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Aardvark Therapeutics recently announced quarterly report
Check out if Aardvark Therapeutics is spiking on competitors!
Click to see if Aardvark Therapeutics had a recent Job posting/layoffs
Check if Aardvark Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Aardvark Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Aardvark Therapeutics launches new products
Funding: Get notified immidiatlly once Aardvark Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Aardvark Therapeutics
Recommended Actions
Find VP level buyers at Aardvark Therapeutics
Find 2 more new buyers
Compare Similar Companies to Aardvark Therapeutics
Compare insights from companies similar to Aardvark Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aardvark Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aardvark Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aardvark Therapeutics.
Aardvark Therapeutics financials insights
Gather financial insights about Aardvark Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$15M
2021
Series B
$29M
2024
Series C
$85M
2025
Stock Offering
$94M
Aardvark Therapeutics Tech Stack
A closer look at the technologies used by Aardvark Therapeutics
Most Recent Scoops
Person-Based
Lawsuits, Legal Affairs
Left Company
Executive Move
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
Aardvark Therapeutics News & Media
AARD DEADLINE: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
Aardvark Therapeutics' shares lost more than 70% of their IPO value across two market events after the Company disclosed a Phase 3 safety pause and then a full FDA clinical hold on ARD-101, which a securities class action alleges corrected earlier representations that the drug was "99% gut-restricted" with minimal systemic exposure Aardvark Therapeutics' shares lost more than 70% of their IPO value across two market events after the Company disclosed a Phase 3 safetyINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against the officers and directors of Aardvark Therapeutics, Inc. (NASDAQ: AARD): Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders...Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Aardvark Therapeutics, Inc. (AARD) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK...Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aardvark Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2017, Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications. The company is headquartered in San Diego, California.... Read More
